Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults-Reference-Cited by-同舟云学术

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

Published:2011-07 Issue:32 Volume:29 Page:5145-5152
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Turley Christine B.,Rupp Richard E.,Johnson Casey,Taylor David N.,Wolfson Julie,Tussey Lynda,Kavita Uma,Stanberry Lawrence,Shaw Alan

Funder

Bill & Melinda Gates Foundation's Global Health program

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference25 articles.

1. Influenza vaccines for the future;Lambert;N Engl J Med,2010

2. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine—Marshfield, Wisconsin, 2007-08 influenza season;CDC;MMWR,2008

3. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada;Skowronski;Vaccine,2007

4. Prospects for universal influenza virus vaccine;Gerhard;Emerg Infect Dis,2006

5. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin;Huleatt;Vaccine,2008

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The development of a human Brucella mucosal vaccine: What should be considered?;Life Sciences;2024-10

2. Assessing population-level target product profiles of universal human influenza A vaccines;Epidemics;2024-09

3. Inserting Omp22 into the flagellin protein, replacing its hypervariable region, results in stronger protection against sepsis caused by Acinetobacter baumannii in a mouse model;2024-08-14

4. Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice;Nature Communications;2024-08-09

5. Mannan‑, VLP-, and flagellin-based adjuvants for allergen-specific immunotherapy: a review of the current literature;Allergo Journal International;2024-07-18